Search

Mass movements and delta collapses are significant sources of tsunamis in lacustrine environments, impacting human societies enormously. Paleotsunamis studies play an essential role in understanding historical events and their consequences, along with their return periods. This study investigates a paleotsunami induced by a subaqueous mass movement during the Younger Dryas to Early Holocene transition, ca. 11,700 years ago in Lake Aiguebelette (NW Alps, France). Utilizing high‐resolution seismic and bathymetric surveys associated with sedimentological, geochemical, and magnetic analyses, we uncovered a paleotsunami triggered by a seismically induced mass transport deposit. Numerical simulations of mass movement have been conducted using a visco‐plastic Herschel‐Bulkley rheological model and corresponding tsunami wave modeled with dispersive and nondispersive models. Our findings reveal for the first time that dispersive effects may be negligible for subaqueous landslides in a relatively small lake. This research reconstructs a previously unreported paleotsunami event and enhances our understanding of tsunami dynamics in lacustrine environments. Plain Language Summary: This study explores an ancient landslide and its ability to potentially generate a tsunami. This event took place in Lake Aiguebelette, located in the NW Alps, France. By applying advanced underwater mapping techniques and computer modeling, we were able to reconstruct the origins and impact of this underwater prehistoric landslide. Our work revealed that this underwater landslide may have triggered a significant tsunami wave. These findings are crucial as they provide new insights into the dynamics of such geological events in lake environments, enhancing our understanding of their potential impacts and aiding in the preparation for future similar hazards. Key Points: Uncovered a 11,700‐year‐old subaqueous landslide‐induced paleotsunami in Lake Aiguebelette (NW Alps, France)Numerical model is constrained to reproduce the available geological dataFound dispersion effects to be of minimal importance in the modeling of this historical tsunami event [ABSTRACT FROM AUTHOR]

A low temperature hydrogen borrowing approach to generate secondary amines using benzimidazole-based N-heterocyclic carbene (BNHC) ruthenium complexes is reported. A series of the piano-stool complexes of the type [(η6-p-cymene)(BNHC)RuCl2] (1a-g) were synthesized via one-pot reaction of the NHC salt precursor, Ag2O, and [RuCl2(p-cymene)]2 and characterized using conventional spectroscopic techniques. The geometry of two precursors, [(η6-p-cymene)(Me4BnMe2BNHCCH2OxMe)RuCl2] (1f) and [(η6-pcymene)(Me5BnMe2BNHCCH2OxMe)RuCl2] (1g), was studied by single crystal X-ray diffraction. These catalysts were found to dehydrogenate alcohols efficiently at temperatures as low as 50 °C to allow Schiff-base condensation and subsequent imine hydrogenation to afford secondary amines. Notably, this ruthenium-based procedure enables the N-alkylation of aromatic and heteroaromatic primary amines with a wide range of primary alcohols in excellent yields of up to 98%. The present methodology is green and water is liberated as the sole byproduct. [ABSTRACT FROM AUTHOR]

Cancer is a complex multifactorial process, unchecked and abrupt division, and cell growth—conventional chemotherapy, along with radiotherapy, is used to treat breast cancer. Due to reduce efficacy and less survival rate, there is a particular need for the discovery of new active anticancer agents. Natural resources such as terrestrial/marine plants or organisms are a promising source for the generation of new therapeutics with improving efficacy. The screening of natural plant extracts and fractions, isolations of phytochemicals, and mechanistic study of those potential compounds play a remarkable role in the development of new therapeutic drugs with increased efficacy. Cancer is a multistage disease with complex signaling cascades. The initial study of screening whole extracts or fractions and later the isolation of secondary compounds and their mechanism of action study gives a clue of potential therapeutic agents for future drug development. The phytochemicals present in extracts/fractions produce remarkable effects due to synergistically targeting multiple signals. In this review, the molecular targets of extracts/ fractions and isolated compounds highlighted. The therapeutic agent's mechanistic targets in drug development focused involves; i) Induction of Apoptosis, ii) modulating cell cycle arrest, iii) Inhibition or suppression of invasion and metastasis and iv) various other pro-survival signaling pathways. The phytochemicals and their modified analogs identified as future potential candidates for anticancer chemotherapy. [ABSTRACT FROM AUTHOR]

Cancer is a complex mechanism involving a series of cellular events. The glycoproteins such as hyaluronan (HA) are a significant element of extracellular matrix (ECM), involve in the onset of cancer developmental process. The pivotal roles of HA in cancer progression depend on dysregulated expression in various cancer. HA, also gain attention due to consideration as a primary ligand of CD44 receptor. The CD44, complex transmembrane receptor protein, due to alternative splicing in the transcription process, various CD44 isoforms predominantly exist. The overexpression of distinct CD44 isoforms (CD44v) standard (CD44s) depends on the tumour type and stage. The receptor proteins, CD44 engage in a variety of biological processes, including cell growth, apoptosis, migration, and angiogenesis. HA-CD44 interaction trigger survival pathways that result in cell proliferation, invasion ultimately complex metastasis. The interaction and binding of ligand-receptor HA-CD44 regulate the downstream cytoskeleton pathways involve in cell survival or cell death. Thus, targeting HA, CD44 (variant and standard) isoform, and HA-CD44 binding consider as an attractive and useful approach towards cancer therapeutics. The use of various inhibitors of HA, hyaluronidases (HYALs), and utilizing targeted Nano-delivery of anticancer agents and antibodies against CD44, peptides gives promising results in vitro and in vivo. However, they are in clinical trials with favourable and unfavourable outcomes, which reflects the need for various modifications in targeting agents and a better understanding of potential targets in tumour progression pathways. [ABSTRACT FROM AUTHOR]